Abstract
Several growth factors, chemokines, adhesion molecules, and proteolytic enzymes important for cell–cell/cell–matrix interactions in atherosclerosis and restenosis are initially synthesized as inactive precursor proteins. Activation of proproteins to biologically active molecules is regulated by limited endoproteolytic cleavage at dibasic amino acid residues. This type of activation typically requires the presence of suitable proprotein convertases (PCs). The PC-isozymes furin and PC5 are expressed in human atherosclerotic lesions and have been found to be up-regulated, following vascular injury in animal models in vivo. In vitro, these PCs can regulate vascular smooth muscle cell and macrophage functions and signaling events, through activation of pro-α-integrins and/or pro-membrane-type matrix metalloproteinases. Integrins link the cytoskeleton with the extracellular matrix and mediate bidirectional signaling and mechanotransduction, whereas matrix metalloproteinases are the major matrix-degrading enzymes. Both activities are required for cell recruitment to the intima. Furthermore, cleavage of extracellular matrix molecules by matrix metalloproteinases potentially contributes to weakening of the fibrous cap, promoting plaque rupture. Based on these recent in vitro and in vivo data, furin and PC5 are potential contributors to the initiation, progression, and complications of atherosclerosis and restenosis. Targeting these PCs may provide future anti-atherosclerotic therapies.




Similar content being viewed by others
References
Ross R (1999) Atherosclerosis—an inflammatory disease. N Engl J Med 340:115–126
Khan BV, Parthasarathy SS, Alexander RW, Medford RM (1995) Modified low density lipoprotein and its constituents augment cytokine-activated vascular cell adhesion molecule-1 gene expression in human vascular endothelial cells. J Clin Invest 95:1262–1270
Gosling J, Slaymaker S, Gu L, Tseng S, Zlot CH, Young SG, Rollins BJ, Charo IF (1999) MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J Clin Invest 103:773–778
Bruemmer D, Collins AR, Noh G, Wang W, Territo M, Arias-Magallona S, Fishbein MC, Blaschke F, Kintscher U, Graf K, Law RE, Hsueh WA (2003) Angiotensin II-accelerated atherosclerosis and aneurysm formation is attenuated in osteopontin-deficient mice. J Clin Invest 112:1318–1331
Wilcox JN, Nelken NA, Coughlin SR, Gordon D, Schall TJ (1994) Local expression of inflammatory cytokines in human atherosclerotic plaques. J Atheroscler Thromb 1:S10–S13
Ikeda T, Shirasawa T, Esaki Y, Yoshiki S, Hirokawa K (1993) Osteopontin mRNA is expressed by smooth muscle-derived foam cells in human atherosclerotic lesions of the aorta. J Clin Invest 92:2814–2820
Matias-Roman S, Galvez BG, Genis L, Yanez-Mo M, de la Rosa G, Sanchez-Mateos P, Sanchez-Madrid F, Arroyo AG (2005) Membrane type 1-matrix metalloproteinase is involved in migration of human monocytes and is regulated through their interaction with fibronectin or endothelium. Blood 105:3956–3964
Dzau VJ, Braun-Dullaeus RC, Sedding DG (2002) Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies. Nat Med 8:1249–1256
Kanda S, Kuzuya M, Ramos MA, Koike T, Yoshino K, Ikeda S, Iguchi A (2000) Matrix metalloproteinase and alphavbeta3 integrin-dependent vascular smooth muscle cell invasion through a type I collagen lattice. Arterioscler Thromb Vasc Biol 20:998–1005
Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM (2000) Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 20:1262–1275
Galis ZS, Sukhova GK, Lark MW, Libby P (1994) Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 94:2493–2503
Shah PK, Falk E, Badimon JJ, Fernandez-Ortiz A, Mailhac A, Villareal-Levy G, Fallon JT, Regnstrom J, Fuster V (1995) Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation 92:1565–1569
Seidah NG, Chretien M (1999) Proprotein and prohormone convertases: a family of subtilases generating diverse bioactive polypeptides. Brain Res 848:45–62
Thomas G (2002) Furin at the cutting edge: from protein traffic to embryogenesis and disease. Nat Rev Mol Cell Biol 3:753–766
Seidah NG, Mowla SJ, Hamelin J, Mamarbachi AM, Benjannet S, Toure BB, Basak A, Munzer JS, Marcinkiewicz J, Zhong M, Barale JC, Lazure C, Murphy RA, Chretien M, Marcinkiewicz M (1999) Mammalian subtilisin/kexin isozyme SKI-1: a widely expressed proprotein convertase with a unique cleavage specificity and cellular localization. Proc Natl Acad Sci U S A 96:1321–1326
Sakai J, Rawson RB, Espenshade PJ, Cheng D, Seegmiller AC, Goldstein JL, Brown MS (1998) Molecular identification of the sterol-regulated luminal protease that cleaves SREBPs and controls lipid composition of animal cells. Mol Cell 2:505–514
Seidah NG, Benjannet S, Wickham L, Marcinkiewicz J, Jasmin SB, Stifani S, Basak A, Prat A, Chretien M (2003) The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci U S A 100:928–933
Benjannet S, Rhainds D, Essalmani R, Mayne J, Wickham L, Jin W, Asselin MC, Hamelin J, Varret M, Allard D, Trillard M, Abifadel M, Tebon A, Attie AD, Rader DJ, Boileau C, Brissette L, Chretien M, Prat A, Seidah NG (2004) NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J Biol Chem 279:48865–48875
Henrich S, Cameron A, Bourenkov GP, Kiefersauer R, Huber R, Lindberg I, Bode W, Than ME (2003) The crystal structure of the proprotein processing proteinase furin explains its stringent specificity. Nat Struct Biol 10:520–526
Takahashi S, Nakagawa T, Banno T, Watanabe T, Murakami K, Nakayama K (1995) Localization of furin to the trans-Golgi network and recycling from the cell surface involves Ser and Tyr residues within the cytoplasmic domain. J Biol Chem 270:28397–28401
Mbikay M, Tadros H, Ishida N, Lerner CP, De Lamirande E, Chen A, El-Alfy M, Clermont Y, Seidah NG, Chretien M, Gagnon C, Simpson EM (1997) Impaired fertility in mice deficient for the testicular germ-cell protease PC4. Proc Natl Acad Sci U S A 94:6842–6846
Marcinkiewicz M, Day R, Seidah NG, Chretien M (1993) Ontogeny of the prohormone convertases PC1 and PC2 in the mouse hypophysis and their colocalization with corticotropin and alpha-melanotropin. Proc Natl Acad Sci U S A 90:4922–4926
Seidah NG, Hamelin J, Mamarbachi M, Dong W, Tardos H, Mbikay M, Chretien M, Day R (1996) cDNA structure, tissue distribution, and chromosomal localization of rat PC7, a novel mammalian proprotein convertase closest to yeast kexin-like proteinases. Proc Natl Acad Sci U S A 93:3388–3393
Taylor NA, Van De Ven WJ, Creemers JW (2003) Curbing activation: proprotein convertases in homeostasis and pathology. FASEB J 17:1215–1227
Zhu X, Zhou A, Dey A, Norrbom C, Carroll R, Zhang C, Laurent V, Lindberg I, Ugleholdt R, Holst JJ, Steiner DF (2002) Disruption of PC1/3 expression in mice causes dwarfism and multiple neuroendocrine peptide processing defects. Proc Natl Acad Sci U S A 99:10293–10298
Roebroek AJ, Umans L, Pauli IG, Robertson EJ, van Leuven F, Van de Ven WJ, Constam DB (1998) Failure of ventral closure and axial rotation in embryos lacking the proprotein convertase Furin. Development 125:4863–4876
Chretien M, Mbikay M, Gaspar L, Seidah NG (1995) Proprotein convertases and the pathophysiology of human diseases: prospective considerations. Proc Assoc Am Physicians 107:47–66
Sarac MS, Peinado JR, Leppla SH, Lindberg I (2004) Protection against anthrax toxemia by hexa-d-arginine in vitro and in vivo. Infect Immun 72:602–605
Stawowy P, Kallisch H, Borges Pereira Stawowy N, Stibenz D, Veinot JP, Grafe M, Seidah NG, Chretien M, Fleck E, Graf K (2005) Immunohistochemical localization of subtilisin/kexin-like proprotein convertases in human atherosclerosis. Virchows Arch 446:351–359
Dubois CM, Blanchette F, Laprise MH, Leduc R, Grondin F, Seidah NG (2001) Evidence that furin is an authentic transforming growth factor-beta1-converting enzyme. Am J Pathol 158:305–316
Negishi M, Lu D, Zhang YQ, Sawada Y, Sasaki T, Kayo T, Ando J, Izumi T, Kurabayashi M, Kojima I, Masuda H, Takeuchi T (2001) Upregulatory expression of furin and transforming growth factor-beta by fluid shear stress in vascular endothelial cells. Arterioscler Thromb Vasc Biol 21:785–790
Blakytny R, Ludlow A, Martin GE, Ireland G, Lund LR, Ferguson MW, Brunner G (2004) Latent TGF-beta 1 activation by platelets. J Cell Physiol 199:67–76
Stawowy P, Margeta C, Kallisch H, Seidah NG, Chretien M, Fleck E, Graf K (2004) Regulation of matrix metalloproteinase MT1-MMP/MMP-2 in cardiac fibroblasts by TGF-beta1 involves furin-convertase. Cardiovasc Res 63:87–97
Gojova A, Brun V, Esposito B, Cottrez F, Gourdy P, Ardouin P, Tedgui A, Mallat Z, Groux H (2003) Specific abrogation of transforming growth factor-beta signaling in T cells alters atherosclerotic lesion size and composition in mice. Blood 102:4052–4058
Campan M, Yoshizumi M, Seidah NG, Lee ME, Bianchi C, Haber E (1996) Increased proteolytic processing of protein tyrosine phosphatase mu in confluent vascular endothelial cells: the role of PC5, a member of the subtilisin family. Biochemistry 35:3797–3802
Woodford-Thomas TA, Rhodes JD, Dixon JE (1992) Expression of a protein tyrosine phosphatase in normal and v-src-transformed mouse 3T3 fibroblasts. J Cell Biol 117:401–414
Koop EA, Gebbink MF, Sweeney TE, Mathy MJ, Heijnen HF, Spaan JA, Voest EE, VanBavel E, Peters SL (2005) Impaired flow-induced dilation in mesenteric resistance arteries from receptor protein tyrosine phosphatase-mu-deficient mice. Am J Physiol Heart Circ Physiol 288:H1218–H1223
Owens GK (1995) Regulation of differentiation of vascular smooth muscle cells. Physiol Rev 75:487–517
Krotz F, Sohn HY, Klauss V, Schiele TM (2005) Intracoronary brachytherapy-clinical state and pathophysiological considerations. Curr Pharm Des 11:421–433
Costa MA, Simon DI (2005) Molecular basis of restenosis and drug-eluting stents. Circulation 111:2257–2273
Gallo R, Padurean A, Jayaraman T, Marx S, Roque M, Adelman S, Chesebro J, Fallon J, Fuster V, Marks A, Badimon JJ (1999) Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation 99:2164–2170
Rowinsky EK (2004) Targeting the molecular target of rapamycin (mTOR). Curr Opin Oncol 16:564–575
Stawowy P, Marcinkiewicz J, Graf K, Seidah N, Chretien M, Fleck E, Marcinkiewicz M (2001) Selective expression of the proprotein convertases furin, PC5, and PC7 in proliferating vascular smooth muscle cells of the rat aorta in vitro. J Histochem Cytochem 49:323–332
Stawowy P, Blaschke F, Kilimnik A, Goetze S, Kallisch H, Chretien M, Marcinkiewicz M, Fleck E, Graf K (2002) Proprotein convertase PC5 regulation by PDGF-BB involves PI3-kinase/p70(s6)-kinase activation in vascular smooth muscle cells. Hypertension 39:399–404
Kamimura H, Konda Y, Yokota H, Takenoshita S, Nagamachi Y, Kuwano H, Takeuchi T (1999) Kex2 family endoprotease furin is expressed specifically in pit-region parietal cells of the rat gastric mucosa. Am J Physiol 277:G183–G190
Blanchette F, Rivard N, Rudd P, Grondin F, Attisano L, Dubois CM (2001) Cross-talk between the p42/p44 MAP kinase and Smad pathways in transforming growth factor beta 1-induced furin gene transactivation. J Biol Chem 276:33986–33994
Servant MJ, Giasson E, Meloche S (1996) Inhibition of growth factor-induced protein synthesis by a selective MEK inhibitor in aortic smooth muscle cells. J Biol Chem 271:16047–16052
Munzer JS, Basak A, Zhong M, Mamarbachi A, Hamelin J, Savaria D, Lazure C, Hendy GN, Benjannet S, Chretien M, Seidah NG (1997) In vitro characterization of the novel proprotein convertase PC7. J Biol Chem 272:19672–19681
Wouters S, Leruth M, Decroly E, Vandenbranden M, Creemers JW, van de Loo JW, Ruysschaert JM, Courtoy PJ (1998) Furin and proprotein convertase 7 (PC7)/lymphoma PC endogenously expressed in rat liver can be resolved into distinct post-Golgi compartments. Biochem J 336(Pt 2):311–316
de Kleijn DP, Sluijter JP, Smit J, Velema E, Richard W, Schoneveld AH, Pasterkamp G, Borst C (2001) Furin and membrane type-1 metalloproteinase mRNA levels and activation of metalloproteinase-2 are associated with arterial remodeling. FEBS Lett 501:37–41
Veinot JP, Prichett-Pejic W, Picard P, Parks W, Schwartz R, Seidah NG, Chretien M (2004) Implications of proprotein convertase 5 (PC5) in the arterial restenotic process in a porcine model. Cardiovasc Pathol 13:241–250
Wei GL, Krasinski K, Kearney M, Isner JM, Walsh K, Andres V (1997) Temporally and spatially coordinated expression of cell cycle regulatory factors after angioplasty. Circ Res 80:418–426
Khatib AM, Siegfried G, Prat A, Luis J, Chretien M, Metrakos P, Seidah NG (2001) Inhibition of proprotein convertases is associated with loss of growth and tumorigenicity of HT-29 human colon carcinoma cells: importance of insulin-like growth factor-1 (IGF-1) receptor processing in IGF-1-mediated functions. J Biol Chem 276:30686–30693
Bassi DE, Lopez De Cicco R, Mahloogi H, Zucker S, Thomas G, Klein-Szanto AJ (2001) Furin inhibition results in absent or decreased invasiveness and tumorigenicity of human cancer cells. Proc Natl Acad Sci U S A 98:10326–10331
Lopez de Cicco R, Bassi DE, Zucker S, Seidah NG, Klein-Szanto AJ (2005) Human carcinoma cell growth and invasiveness is impaired by the propeptide of the ubiquitous proprotein convertase furin. Cancer Res 65:4162–4171
Hallenberger S, Bosch V, Angliker H, Shaw E, Klenk HD, Garten W (1992) Inhibition of furin-mediated cleavage activation of HIV-1 glycoprotein gp160. Nature 360:358–361
Stawowy P, Kallisch H, Kilimnik A, Margeta C, Seidah NG, Chretien M, Fleck E, Graf K (2004) Proprotein convertases regulate insulin-like growth factor 1-induced membrane-type 1 matrix metalloproteinase in VSMCs via endoproteolytic activation of the insulin-like growth factor-1 receptor. Biochem Biophys Res Commun 321:531–538
Stawowy P, Kallisch H, Veinot JP, Kilimnik A, Prichett W, Goetze S, Seidah NG, Chretien M, Fleck E, Graf K (2004) Endoproteolytic activation of alpha (v) integrin by proprotein convertase PC5 is required for vascular smooth muscle cell adhesion to vitronectin and integrin-dependent signaling. Circulation 109:770–776
Marcinkiewicz M, Marcinkiewicz J, Chen A, Leclaire F, Chretien M, Richardson P (1999) Nerve growth factor and proprotein convertases furin and PC7 in transected sciatic nerves and in nerve segments cultured in conditioned media: their presence in Schwann cells, macrophages, and smooth muscle cells. J Comp Neurol 403:471–485
Stawowy P, Meyborg H, Stibenz D, Borges Pereira Stawowy N, Roser M, Thanabalasingam U, Veinot JP, Chretien M, Seidah NG, Fleck E, Graf K (2005) Furin-like proprotein convertases are central regulators of the membrane type matrix metalloproteinase–pro-matrix metalloproteinase-2 proteolytic cascade in atherosclerosis. Circulation 111:2820–2827
Osterud B, Bjorklid E (2003) Role of monocytes in atherogenesis. Physiol Rev 83:1069–1112
Weintraub AS, Schnapp LM, Lin X, Taubman MB (2000) Osteopontin deficiency in rat vascular smooth muscle cells is associated with an inability to adhere to collagen and increased apoptosis. Lab Invest 80:1603–1615
Meredith JE Jr, Fazeli B, Schwartz MA (1993) The extracellular matrix as a cell survival factor. Mol Biol Cell 4:953–961
Mercurius KO, Morla AO (1998) Inhibition of vascular smooth muscle cell growth by inhibition of fibronectin matrix assembly. Circ Res 82:548–556
Koyama H, Raines EW, Bornfeldt KE, Roberts JM, Ross R (1996) Fibrillar collagen inhibits arterial smooth muscle proliferation through regulation of Cdk2 inhibitors. Cell 87:1069–1078
Bosman FT, Stamenkovic I (2003) Functional structure and composition of the extracellular matrix. J Pathol 200:423–428
Juliano RL, Reddig P, Alahari S, Edin M, Howe A, Aplin A (2004) Integrin regulation of cell signalling and motility. Biochem Soc Trans 32:443–446
English WR, Puente XS, Freije JM, Knauper V, Amour A, Merryweather A, Lopez-Otin C, Murphy G (2000) Membrane type 4 matrix metalloproteinase (MMP17) has tumor necrosis factor-alpha convertase activity but does not activate pro-MMP2. J Biol Chem 275:14046–14055
Deryugina EI, Ratnikov BI, Postnova TI, Rozanov DV, Strongin AY (2002) Processing of integrin alpha(v) subunit by membrane type 1 matrix metalloproteinase stimulates migration of breast carcinoma cells on vitronectin and enhances tyrosine phosphorylation of focal adhesion kinase. J Biol Chem 277:9749–9756
McQuibban GA, Gong JH, Tam EM, McCulloch CA, Clark-Lewis I, Overall CM (2000) Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science 289:1202–1206
Yu Q, Stamenkovic I (2000) Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev 14:163–176
Berthet V, Rigot V, Champion S, Secchi J, Fouchier F, Marvaldi J, Luis J (2000) Role of endoproteolytic processing in the adhesive and signaling functions of alpha v beta 5 integrin. J Biol Chem 275:33308–33313
Lissitzky JC, Luis J, Munzer JS, Benjannet S, Parat F, Chretien M, Marvaldi J, Seidah NG (2000) Endoproteolytic processing of integrin pro-alpha subunits involves the redundant function of furin and proprotein convertase (PC) 5A, but not paired basic amino acid converting enzyme (PACE) 4, PC5B or PC7. Biochem J 346:133–138
Kang T, Nagase H, Pei D (2002) Activation of membrane-type matrix metalloproteinase 3 zymogen by the proprotein convertase furin in the trans-Golgi network. Cancer Res 62:675–681
Yana I, Weiss SJ (2000) Regulation of membrane type-1 matrix metalloproteinase activation by proprotein convertases. Mol Biol Cell 11:2387–2401
Suzuki S, Argraves WS, Pytela R, Arai H, Krusius T, Pierschbacher MD, Ruoslahti E (1986) cDNA and amino acid sequences of the cell adhesion protein receptor recognizing vitronectin reveal a transmembrane domain and homologies with other adhesion protein receptors. Proc Natl Acad Sci U S A 83:8614–8618
Hynes RO (1992) Integrins: versatility, modulation, and signaling in cell adhesion. Cell 69:11–25
Dufourcq P, Louis H, Moreau C, Daret D, Boisseau MR, Lamaziere JM, Bonnet J (1998) Vitronectin expression and interaction with receptors in smooth muscle cells from human atheromatous plaque. Arterioscler Thromb Vasc Biol 18:168–176
Dufourcq P, Couffinhal T, Alzieu P, Daret D, Moreau C, Duplaa C, Bonnet J (2002) Vitronectin is up-regulated after vascular injury and vitronectin blockade prevents neointima formation. Cardiovasc Res 53:952–962
Slepian MJ, Massia SP, Dehdashti B, Fritz A, Whitesell L (1998) Beta 3-integrins rather than beta 1-integrins dominate integrin–matrix interactions involved in postinjury smooth muscle cell migration. Circulation 97:1818–1827
Hoshiga M, Alpers CE, Smith LL, Giachelli CM, Schwartz SM (1995) Alpha-v beta-3 integrin expression in normal and atherosclerotic artery. Circ Res 77:1129–1135
Liaw L, Skinner MP, Raines EW, Ross R, Cheresh DA, Schwartz SM, Giachelli CM (1995) The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins. Role of alpha v beta 3 in smooth muscle cell migration to osteopontin in vitro. J Clin Invest 95:713–724
Weerasinghe D, McHugh KP, Ross FP, Brown EJ, Gisler RH, Imhof BA (1998) A role for the alpha v beta 3 integrin in the transmigration of monocytes. J Cell Biol 142:595–607
Coleman KR, Braden GA, Willingham MC, Sane DC (1999) Vitaxin, a humanized monoclonal antibody to the vitronectin receptor (alpha v beta 3), reduces neointimal hyperplasia and total vessel area after balloon injury in hypercholesterolemic rabbits. Circ Res 84:1268–1276
Bishop GG, McPherson JA, Sanders JM, Hesselbacher SE, Feldman MJ, McNamara CA, Gimple LW, Powers ER, Mousa SA, Sarembock IJ (2001) Selective alpha (v) beta (3)-receptor blockade reduces macrophage infiltration and restenosis after balloon angioplasty in the atherosclerotic rabbit. Circulation 103:1906–1911
Patel SS, Thiagarajan R, Willerson JT, Yeh ET (1998) Inhibition of alpha 4 integrin and ICAM-1 markedly attenuate macrophage homing to atherosclerotic plaques in ApoE-deficient mice. Circulation 97:75–81
Stawowy P, Graf K, Goetze S, Roser M, Chretien M, Seidah NG, Fleck E, Marcinkiewicz M (2003) Coordinated regulation and colocalization of alphav integrin and its activating enzyme proprotein convertase PC5 in vivo. Histochem Cell Biol 119:239–245
Delwel GO, Hogervorst F, Sonnenberg A (1996) Cleavage of the alpha 6A subunit is essential for activation of the alpha 6A beta 1 integrin by phorbol 12-myristate 13-acetate. J Biol Chem 271:7293–7296
Benjannet S, Savaria D, Laslop A, Munzer JS, Chretien M, Marcinkiewicz M, Seidah NG (1997) Alpha 1-antitrypsin Portland inhibits processing of precursors mediated by proprotein convertases primarily within the constitutive secretory pathway. J Biol Chem 272:26210–26218
Walker JL, Zhang L, Menko AS (2002) A signaling role for the uncleaved form of alpha 6 integrin in differentiating lens fiber cells. Dev Biol 251:195–205
Schaller MD, Hildebrand JD, Shannon JD, Fox JW, Vines RR, Parsons JT (1994) Autophosphorylation of the focal adhesion kinase, pp125FAK, directs SH2-dependent binding of pp60src. Mol Cell Biol 14:1680–1688
Chen HC, Guan JL (1994) Association of focal adhesion kinase with its potential substrate phosphatidylinositol 3-kinase. Proc Natl Acad Sci U S A 91:10148–10152
Cary LA, Chang JF, Guan JL (1996) Stimulation of cell migration by overexpression of focal adhesion kinase and its association with Src and Fyn. J Cell Sci 109:1787–1794
Reiske HR, Kao SC, Cary LA, Guan JL, Lai JF, Chen HC (1999) Requirement of phosphatidylinositol 3-kinase in focal adhesion kinase-promoted cell migration. J Biol Chem 274:12361–12366
Lin TH, Aplin AE, Shen Y, Chen Q, Schaller M, Romer L, Aukhil I, Juliano RL (1997) Integrin-mediated activation of MAP kinase is independent of FAK: evidence for dual integrin signaling pathways in fibroblasts. J Cell Biol 136:1385–1395
Brooks PC, Stromblad S, Sanders LC, von Schalscha TL, Aimes RT, Stetler-Stevenson WG, Quigley JP, Cheresh DA (1996) Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell 85:683–693
Deryugina EI, Ratnikov B, Monosov E, Postnova TI, DiScipio R, Smith JW, Strongin AY (2001) MT1-MMP initiates activation of pro-MMP-2 and integrin alpha v beta 3 promotes maturation of MMP-2 in breast carcinoma cells. Exp Cell Res 263:209–223
Giannelli G, Falk-Marzillier J, Schiraldi O, Stetler-Stevenson WG, Quaranta V (1997) Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science 277:225–228
Pauly RR, Passaniti A, Bilato C, Monticone R, Cheng L, Papadopoulos N, Gluzband YA, Smith L, Weinstein C, Lakatta EG et al (1994) Migration of cultured vascular smooth muscle cells through a basement membrane barrier requires type IV collagenase activity and is inhibited by cellular differentiation. Circ Res 75:41–54
Zempo N, Koyama N, Kenagy RD, Lea HJ, Clowes AW (1996) Regulation of vascular smooth muscle cell migration and proliferation in vitro and in injured rat arteries by a synthetic matrix metalloproteinase inhibitor. Arterioscler Thromb Vasc Biol 16:28–33
Kai H, Ikeda H, Yasukawa H, Kai M, Seki Y, Kuwahara F, Ueno T, Sugi K, Imaizumi T (1998) Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 32:368–372
Visse R, Nagase H (2003) Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 92:827–839
Newby AC (2005) Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev 85:1–31
Polette M, Birembaut P (1998) Membrane-type metalloproteinases in tumor invasion. Int J Biochem Cell Biol 30:1195–1202
Galis ZS, Muszynski M, Sukhova GK, Simon-Morrissey E, Unemori EN, Lark MW, Amento E, Libby P (1994) Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circ Res 75:181–189
Rajavashisth TB, Xu XP, Jovinge S, Meisel S, Xu XO, Chai NN, Fishbein MC, Kaul S, Cercek B, Sharifi B, Shah PK (1999) Membrane type 1 matrix metalloproteinase expression in human atherosclerotic plaques: evidence for activation by proinflammatory mediators. Circulation 99:3103–3109
Xu XP, Meisel SR, Ong JM, Kaul S, Cercek B, Rajavashisth TB, Sharifi B, Shah PK (1999) Oxidized low-density lipoprotein regulates matrix metalloproteinase-9 and its tissue inhibitor in human monocyte-derived macrophages. Circulation 99:993–998
Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, Goldberg GI (1995) Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem 270:5331–5338
Will H, Atkinson SJ, Butler GS, Smith B, Murphy G (1996) The soluble catalytic domain of membrane type 1 matrix metalloproteinase cleaves the propeptide of progelatinase A and initiates autoproteolytic activation. Regulation by TIMP-2 and TIMP-3. J Biol Chem 271:17119–17123
Aimes RT, Quigley JP (1995) Matrix metalloproteinase-2 is an interstitial collagenase. Inhibitor-free enzyme catalyzes the cleavage of collagen fibrils and soluble native type I collagen generating the specific 3/4- and 1/4-length fragments. J Biol Chem 270:5872–5876
Shofuda KI, Hasenstab D, Kenagy RD, Shofuda T, Li ZY, Lieber A, Clowes AW (2001) Membrane-type matrix metalloproteinase-1 and -3 activity in primate smooth muscle cells. FASEB J 15:2010–2012
Zahradka P, Harding G, Litchie B, Thomas S, Werner JP, Wilson DP, Yurkova N (2004) Activation of MMP-2 in response to vascular injury is mediated by phosphatidylinositol 3-kinase-dependent expression of MT1-MMP. Am J Physiol 287:H2861–H2870
Rozanov DV, Strongin AY (2003) Membrane type-1 matrix metalloproteinase functions as a proprotein self-convertase. Expression of the latent zymogen in Pichia pastoris, autolytic activation, and the peptide sequence of the cleavage forms. J Biol Chem 278:8257–8260
Sato T, Kondo T, Fujisawa T, Seiki M, Ito A (1999) Furin-independent pathway of membrane type 1-matrix metalloproteinase activation in rabbit dermal fibroblasts. J Biol Chem 274:37280–37284
Welgus HG, Campbell EJ, Cury JD, Eisen AZ, Senior RM, Wilhelm SM, Goldberg GI (1990) Neutral metalloproteinases produced by human mononuclear phagocytes. Enzyme profile, regulation, and expression during cellular development. J Clin Invest 86:1496–1502
Wesley RB II, Meng X, Godin D, Galis ZS (1998) Extracellular matrix modulates macrophage functions characteristic to atheroma: collagen type I enhances acquisition of resident macrophage traits by human peripheral blood monocytes in vitro. Arterioscler Thromb Vasc Biol 18:432–440
Worley JR, Baugh MD, Hughes DA, Edwards DR, Hogan A, Sampson MJ, Gavrilovic J (2003) Metalloproteinase expression in PMA-stimulated THP-1 cells. Effects of peroxisome proliferator-activated receptor-gamma (PPAR gamma) agonists and 9-cis-retinoic acid. J Biol Chem 278:51340–51346
Chase AJ, Bond M, Crook MF, Newby AC (2002) Role of nuclear factor-kappa B activation in metalloproteinase-1, -3, and -9 secretion by human macrophages in vitro and rabbit foam cells produced in vivo. Arterioscler Thromb Vasc Biol 22:765–771
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Stawowy, P., Fleck, E. Proprotein convertases furin and PC5: targeting atherosclerosis and restenosis at multiple levels. J Mol Med 83, 865–875 (2005). https://doi.org/10.1007/s00109-005-0723-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00109-005-0723-8